Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2040

Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.

Patents
1,866

Quick answer

1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10806791

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10806794

    Protease inhibitors having enhanced features

    Nektar Therapeutics · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10806807

    TCO conjugates and methods for delivery of therapeutic agents

    The Regents of the University of California · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10807951

    mTORC1 modulators

    The Regents of the University of California · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10806780

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10808020

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10815480

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10815305

    Methods of treating inflammatory conditions

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10813366

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10813885

    Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances

    Jazz Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10813913

    Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10813956

    Methods for making and using antimicrobial peptides

    Regents of the University of Minnesota · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10814013

    Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    The Board of Regents of the University of Texas System · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10815239

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10815301

    Anti-CD30 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10815487

    Chimeric antigen receptors targeting B-cell maturation antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10813894

    Methods of inhibiting pain

    The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10813899

    Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

    OVID THERAPEUTICS INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10814010

    FOXC2 inhibitor and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10813909

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10813918

    Use of Gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10813917

    Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

    MedRegen, LLC · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10813929

    Treating cancer with ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10813934

    Sirtuin modulators as inhibitors of cytomegalovirus

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10813952

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10813993

    Display platform from bacterial spore coat proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10814006

    Fluorescent prodrugs

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10814007

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10813961

    Powder formulation having a function of enhancing immunity and method for preparing the same

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10814043

    Cross-linked fatty acid-based biomaterials

    ATRIUM MEDICAL CORPORATION · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10815229

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10815231

    [1,2,4] triazolo [1,5-a] pyridine derivative and crystalline form thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10815206

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10815219

    2,4-diaminoquinazoline derivatives for inhibiting endoplasmic reticulum (ER) stress

    The Board of Regents of the University of Oklahoma · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10815225

    Antiproliferation compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10815250

    AhR modulators

    IDEAYA Biosciences, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10815276

    Cell penetrating peptides and methods of making and using thereof

    Entrada Therapeutics, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10815271

    Structure-based peptide inhibitors of alpha-synuclein aggregation

    The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10815295

    Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10815266

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10815285

    Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10815455

    Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

    Vaximm AG · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10815463

    Messenger UNA molecules and uses thereof

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10815483

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10815485

    RNA interference in skin indications

    Phio Pharmaceuticals Corp. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10815484

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10815488

    Chimeric antigen receptors targeting B-cell maturation antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. EP 3728594

    MATERIALIEN UND VERFAHREN ZUR BEHANDLUNG DES USHER-SYNDROMS TYP 2A

    CRISPR THERAPEUTICS AG [CH] · Granted Wed Oct 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Oct 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2040?

1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.